Not medical advice. Talk to your provider before using any peptide.
Full disclaimerBPC-157 vs GHK-Cu
Peptide Schedule Research TeamReviewed Apr 202629 Citations
Side-by-side comparison of dosage, benefits, and side effects.
A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were animal studies. One was clinical. That ratio says a lot about where the science stands right now. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. It promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendons and ligaments. One property separates it from most peptides: it survives stomach acid. Oral dosing works, particularly for gut applications, because the peptide reaches intestinal tissue without being degraded. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. On April 15, 2026, HHS Secretary Kennedy removed BPC-157 and 11 other peptides from Category 2. PCAC review begins July 2026, with compounding access projected for late 2026 to mid-2027. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.
View full guide →Four thousand genes. That's the number GHK-Cu flips toward repair when it binds to human cells, according to gene expression profiling by Pickart's group (PMID 25789553, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in a silicosis lung model with human biomarker data (PMID 38879894), expanding the peptide's research footprint beyond skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
View full guide →At a Glance
| Attribute |  BPC-157 |  GHK-Cu |
|---|---|---|
| Category | Healing & Recovery | Anti-Aging |
| Safety Grade | C | A |
| Half-Life | ~30 min plasma (functional tissue activity ~4 hours) | ~1 hour |
| Route | Subcutaneous (near injury) or Oral | Subcutaneous or Topical |
| Vial Sizes | 5mg, 10mg | 5mg, 50mg |
| Beginner Dose | 250mcg 2x Daily | 1000mcg Daily |
| Moderate Dose | 500mcg Daily | 2500mcg Daily |
| Aggressive Dose | 500mcg 2x Daily | 3000mcg Daily |
| Dosing Source | Community | Community |
| Side Effects | About 30 humans have been formally studied across all BPC-157 publications combined. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much. At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs. Anxiety and panic attacks are the most commonly reported serious community side effects. BPC-157 modulates both dopamine and serotonin systems in animal studies (Sikiric and colleagues, PMID 9073154). Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect. Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week. Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses. Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing. Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 vendors; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination. Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber. | The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance. Copper toxicity is the second concern worth taking seriously. At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. But continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked. Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying. Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds. At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction. Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community. Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction. Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber. |
Key Differences
- BPC-157 promotes angiogenesis and tendon/ligament repair; GHK-Cu stimulates collagen synthesis and gene repair.
- BPC-157 is best injected near the injury site; GHK-Cu works both systemically (injection) and topically.
- BPC-157 is primarily a healing peptide; GHK-Cu has both healing and anti-aging applications.
- BPC-157 has stronger evidence for gut healing; GHK-Cu has stronger evidence for skin and hair.
When to Choose BPC-157
- Acute injury repair: tendons, ligaments, joints
- Gut healing and GI repair are priorities
- You need localized healing at a specific injury site
- Post-surgical recovery
When to Choose GHK-Cu
- Skin rejuvenation and wound healing are goals
- Anti-aging gene expression modulation is a priority
- You want topical application options
- Hair growth and scalp health are additional goals
Can You Stack BPC-157 + GHK-Cu?
BPC-157 + GHK-Cu is part of the total recovery stack. BPC-157 handles deep tissue repair while GHK-Cu promotes collagen and gene expression: highly complementary.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.